Human in vivo stable isotope labeling kinetics (iSILK) to quantify brain amyloid plaque kinetics
人体内稳定同位素标记动力学 (iSILK) 用于量化脑淀粉样斑块动力学
基本信息
- 批准号:10509111
- 负责人:
- 金额:$ 41.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAducanumabAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAmyloidAmyloid beta-ProteinAntibodiesArchitectureAreaAutopsyBasal GangliaBiochemicalBiological MarkersBrainBrain StemBrain regionCerebellumCerebrospinal FluidCerebrumChemicalsClinicClinicalClinical TrialsCognitiveCoupledDepositionDevelopmentDiagnosticDiffuseDiseaseEvaluationExcisionFDA approvedFreezingFrequenciesGoalsGrowthHematological DiseaseHumanImageImmunoprecipitationImpaired cognitionIndividualIntercellular FluidIsotope LabelingIsotopesKineticsKnowledgeLabelLaboratoriesLasersLifeMeasurementMeasuresMetabolicMicroscopicMidbrain structureModelingMolecularMolecular ConformationMonitorMorphologyN-terminalNeocortexNitrogenOral IngestionPathogenesisPathogenicityPathologicPatientsPeptidesPharmaceutical PreparationsPhasePlasmaPositron-Emission TomographyProtein IsoformsProteinsPyroglutamateResearchResolutionRoleSamplingSenile PlaquesSliceSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSpectrometry, Mass, Secondary IonSpirulina preparationStable Isotope LabelingStainsStructureTimeTissuesTo specifyWithholding Treatmentabeta accumulationamyloid pathologyamyloid structureantibody detectionbasebeta-site APP cleaving enzyme 1brain parenchymabrain tissueclinically relevantcohortconformational conversiondensitydiencephalonexperimental studyfluorescence imaginghospice environmenthuman tissueimaging modalityin vivoinhibitorinsightmass spectrometric imagingmouse modelnanometernanoscalenew therapeutic targetnovel markertargeted treatmenttau Proteinstreatment strategy
项目摘要
Project summary / abstract
Given the recent FDA approval of an antibody-based drug that can remove amyloid plaques as measured
by positron-emission tomography targeting amyloid (PET-amyloid) (aducanamab1), the FDA approval of the
Precivity-AD blood test2, and applications submitted for accelerated approval of lecanemab and donanemab –
antibody-based drugs also shown to reduce plaque by PET-amyloid imaging3–5 – there is an urgent need to
better understand the natural amyloid-beta (Aβ) turnover in plaques.
The overall goal of this proposal is to quantitatively characterize the rate of Aβ turnover within plaques in
vivo, in human brain tissue at various stages of Alzheimer's disease (AD) using stable isotope labeling kinetics
(SILK). That multiple antibody-based drugs nearly completely remove plaques as measured by PET3–5, taken
together with a reduction in the rate of cognitive decline, supports a role for amyloid pathology as critical driver
of AD pathogenesis. However, the duration and possible cessation of treatment is partly dependent on whether
amyloid plaques continue to grow and turn over. Other drugs (e.g. BACE inhibitors) can stop amyloid plaque
growth with minimal reversal of plaque load (~4%/year by PET), suggesting that there is some natural slow
turnover of amyloid plaques. Drug trials and clinical use of anti-amyloid therapies thus must be based on
accurate models of natural plaque growth.
Very recently, microscopic resolution of in vivo metabolic growth of human amyloid plaques was achieved
by combining SILK with mass spectrometric-based imaging methods (“iSILK”) to better characterize protein and
peptide kinetics within brain parenchyma. Specifically, the Bateman laboratory used nanoscale secondary ion
mass spectrometry (NanoSIMS) coupled to SILK to directly image the distribution and rate of protein deposition
in plaques at the nanometer level in postmortem tissue from 3 human patients with AD6. However, NanoSIMS
imaging fails to specify which molecules contain the detected isotopes. In contrast, matrix-assisted laser
desorption / ionization (MALDI) mass spectrometry-based imaging (MALDI-IMS) allows chemically-specific Aβ
peptide imaging of pathologic structures in AD mouse models and postmortem brain, which has been pioneered
by the Hanrieder lab7–10. Consequently, the group very recently demonstrated MALDI in combination with SILK
to follow plaque formation dynamics10.
Using postmortem tissue from human patients previously labeled during life by oral ingestion of 15N-
labeled spirulina, we will characterize Aβ turnover by MALDI-IMS in brains with a spectrum of AD pathology.
These measurements will inform a compartmental model of AD-related protein kinetics starting at the
microscopic structure of the plaque and extending throughout the body, a particularly important model in the
dawning era of clinically-approved diagnostic biomarkers2, disease-modifying therapies3–5, and the critical need
for a precise understanding of the earliest signs of AD.
项目摘要 /摘要
考虑到FDA最近获得了基于抗体的药物的批准,该药物可以根据测量去除淀粉样蛋白斑块
通过靶向淀粉样蛋白(PET-淀粉样蛋白)(ADUCANAMAB1)的正电子发射断层扫描,FDA的批准
Presitivity-AD血液测试2,以及提交的申请,以加速lecanemab和Donanemab的批准 -
基于抗体的药物还表明可以减少宠物淀粉样蛋白成像3-5 - 迫切需要
更好地了解斑块中天然淀粉样β(Aβ)的周转率。
该提案的总体目标是定量地表征斑块中Aβ更新的速率
体内,使用稳定的同位素标记动力学
(丝绸)。通过PET3-5测量的多种基于抗体的药物几乎完全清除了斑块
加上认知能力下降速度的降低,支持淀粉样病理作为关键驱动因素的作用
AD发病机理。但是,治疗的持续时间和可能的停止部分取决于是否是否
淀粉样斑块继续增长和翻转。其他药物(例如BACE抑制剂)可以阻止淀粉样斑块
斑块负荷的最小逆转(pet约4%)的生长,表明有一些自然慢
淀粉样斑块的营业额。因此,抗淀粉样疗法的药物试验和临床使用必须基于
天然斑块生长的准确模型。
最近,实现了人体淀粉样斑的体内代谢生长的微观分辨率
通过将丝与质谱基于质谱的成像方法(“ isilk”)结合起来,以更好地表征蛋白质和
脑实质中的肽动力学。具体而言,贝特曼实验室使用纳米级辅助离子
质谱法(纳米sims)与丝绸耦合,直接成像蛋白质沉积的分布和速率
在3名AD6患者的尸体组织中的纳米水平的斑块中。但是,纳米菌
成像无法指定哪些分子包含检测到的同位素。相反,矩阵辅助激光器
解吸 /电离(MALDI)质谱成像(MALDI-IM)允许化学特异性Aβ
AD小鼠模型和验尸大脑中病理结构的肽成像
由Hanrieder Lab7-10。因此,该小组最近表现出与丝绸结合的Maldi
遵循斑块形成动力学10。
使用先前通过口服摄入15N-的人类患者的死后组织
标记为螺旋藻,我们将表征MALDI-IM在具有多种AD病理学的大脑中的Aβ更新。
这些测量将为广告相关蛋白动力学的隔室模型提供信息
斑块的微观结构并遍及整个身体,这是一个特别重要的模型
临床批准的诊断生物标志物2,疾病改良疗法的DAWNing ERA3-5和关键需求
为了确切地了解AD的最早迹象。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Correlative Chemical Imaging and Spatial Chemometrics Delineate Alzheimer Plaque Heterogeneity at High Spatial Resolution.
- DOI:10.1021/jacsau.2c00492
- 发表时间:2023-03-27
- 期刊:
- 影响因子:8
- 作者:Wehrli, Patrick M;Ge, Junyue;Michno, Wojciech;Koutarapu, Srinivas;Dreos, Ambra;Jha, Durga;Zetterberg, Henrik;Blennow, Kaj;Hanrieder, Jorg
- 通讯作者:Hanrieder, Jorg
Correlative Chemical Imaging Identifies Amyloid Peptide Signatures of Neuritic Plaques and Dystrophy in Human Sporadic Alzheimer's Disease.
相关化学成像识别人类散发性阿尔茨海默病神经炎斑块和营养不良的淀粉样肽特征。
- DOI:10.1089/brain.2022.0047
- 发表时间:2023
- 期刊:
- 影响因子:3.4
- 作者:Koutarapu,Srinivas;Ge,Junyue;Jha,Durga;Blennow,Kaj;Zetterberg,Henrik;Lashley,Tammaryn;Michno,Wojciech;Hanrieder,Jörg
- 通讯作者:Hanrieder,Jörg
Tetramodal Chemical Imaging Delineates the Lipid-Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer's Disease Models.
- DOI:10.1021/acs.analchem.2c05302
- 发表时间:2023-03-14
- 期刊:
- 影响因子:7.4
- 作者:Ge, Junyue;Koutarapu, Srinivas;Jha, Durga;Dulewicz, Maciej;Zetterberg, Henrik;Blennow, Kaj;Hanrieder, Joerg
- 通讯作者:Hanrieder, Joerg
Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer's dementias.
- DOI:10.1111/jnc.15694
- 发表时间:2022-11
- 期刊:
- 影响因子:4.7
- 作者:
- 通讯作者:
Mass Spectrometry Imaging in Alzheimer's Disease
- DOI:10.1089/brain.2022.0057
- 发表时间:2023-04-24
- 期刊:
- 影响因子:3.4
- 作者:Ikegawa,Masaya;Kakuda,Nobuto;Hanrieder,Jorg
- 通讯作者:Hanrieder,Jorg
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jorg Hanrieder其他文献
Jorg Hanrieder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jorg Hanrieder', 18)}}的其他基金
Understanding Amyloid Pathology - Multiomic Activity Imaging of Plaque Formation Dynamics (AmyMAP)
了解淀粉样蛋白病理学 - 斑块形成动力学的多组学活性成像 (AmyMAP)
- 批准号:
10693962 - 财政年份:2022
- 资助金额:
$ 41.1万 - 项目类别:
Understanding Amyloid Pathology - Multiomic Activity Imaging of Plaque Formation Dynamics (AmyMAP)
了解淀粉样蛋白病理学 - 斑块形成动力学的多组学活性成像 (AmyMAP)
- 批准号:
10516489 - 财政年份:2022
- 资助金额:
$ 41.1万 - 项目类别:
相似海外基金
Development of First-in-Class PDE5/HAT Directed LigandsModulating Molecular Pathways involved in Synaptic Plasticity
开发一流的 PDE5/HAT 定向配体调节参与突触可塑性的分子途径
- 批准号:
10654103 - 财政年份:2023
- 资助金额:
$ 41.1万 - 项目类别:
Advancing Geriatrics Infrastructure and Network Growth (AGING) Initiative
推进老年病学基础设施和网络发展 (AGING) 计划
- 批准号:
10732291 - 财政年份:2023
- 资助金额:
$ 41.1万 - 项目类别:
Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease
开发一种新颖的再生疗法来逆转阿尔茨海默氏病的突触损失
- 批准号:
10707700 - 财政年份:2023
- 资助金额:
$ 41.1万 - 项目类别:
Innovative precision medicine methods in subgroup identification for Alzheimer's disease
阿尔茨海默病亚组鉴定的创新精准医学方法
- 批准号:
10740649 - 财政年份:2023
- 资助金额:
$ 41.1万 - 项目类别:
Overcoming proteasome impairment with small molecules
用小分子克服蛋白酶体损伤
- 批准号:
10427952 - 财政年份:2022
- 资助金额:
$ 41.1万 - 项目类别: